Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

INMB

INmune Bio Inc

Apr 13 • 04:00PM ET

1.24

+0.06 5.08 %

Healthcare • Biotechnology • USA • NASD

Peers: ABUS SLNO CYPH TNXP ONCY PDSB IMUX BGMS PRQR LITS

| Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL ITWO UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.92	Insider Own	17.01%	Shs Outstand	26.59M	Perf Week	0.81%
Market Cap	32.97M	Forward P/E	-	EPS next Y	-0.72	Insider Trans	0.00%	Shs Float	22.06M	Perf Month	-6.77%
Enterprise Value	9.25M	PEG	-	EPS next Q	-0.24	Inst Own	19.36%	Short Float	15.53%	Perf Quarter	-16.78%
Income	-45.93M	P/S	659.30	EPS this Y	58.47%	Inst Trans	2.09%	Short Ratio	7.85	Perf Half Y	-37.37%
Sales	0.05M	P/B	1.40	EPS next Y	7.23%	ROA	-127.75%	Short Interest	3.43M	Perf YTD	-20.51%
Book/sh	0.88	P/C	1.33	EPS next 5Y	37.46%	ROE	-165.16%	52W High	11.64 -89.35%	Perf Year	-83.20%
Cash/sh	0.93	P/FCF	-	EPS past 3/5Y	-6.80% -12.95%	ROIC	-191.91%	52W Low	1.09 13.76%	Perf 3Y	-85.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-48.87% 35.58%	Gross Margin	-	Volatility	7.92% 7.09%	Perf 5Y	-88.95%
Dividend TTM	-	EV/Sales	184.90	EPS Y/Y TTM	9.63%	Oper. Margin	-61738.00%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.55	Sales Y/Y TTM	257.14%	Profit Margin	-91866.00%	RSI (14)	48.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.55	EPS Q/Q	52.14%	SMA20	1.56%	Beta	0.91	Target Price	7.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-6.77%	Rel Volume	0.60	Prev Close	1.18
Employees	21	LT Debt/Eq	0.02	Earnings	Mar 30 AMC	SMA200	-33.23%	Avg Volume	436.63K	Price	1.24
IPO	Feb 04, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.74% -	Trades		Volume	263,283	Change	5.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform	$0.60
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$23
Oct-21-24	Initiated	Alliance Global Partners	Buy	$20
Sep-27-24	Initiated	Raymond James	Outperform	$18
Aug-22-24	Initiated	Scotiabank	Sector Outperform	$22
Jun-01-23	Initiated	Robert W. Baird	Outperform	$16
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral	$14 → $7
Jul-07-21	Reiterated	Maxim Group	Buy	$32 → $42
Apr-21-21	Initiated	B. Riley Securities	Buy	$29
Jan-22-21	Reiterated	Maxim Group	Buy	$16 → $32
Sep-01-20	Initiated	BTIG Research	Buy	$23
Jul-15-20	Reiterated	H.C. Wainwright	Buy	$7 → $20

Show Previous Ratings

Mar-31-26 08:30AM	INmune Bio, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-30-26 11:01PM	INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
04:00PM	INmune Bio Inc. Announces 2025 Results and Provides Business Update (GlobeNewswire)
Mar-24-26 08:00AM	INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. (GlobeNewswire)
Mar-19-26 08:00AM	INmune Bio's MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer's Disease (GlobeNewswire)
06:11AM	Loading…
Mar-11-26 06:11AM	INmune Bio upgraded to Buy from Neutral at Lucid Capital (TipRanks) +10.94%
Feb-23-26 09:25AM	INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar (GlobeNewswire)
Feb-19-26 12:15PM	INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom for RDEB (GlobeNewswire)
Feb-12-26 07:00AM	INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's Disease (GlobeNewswire) -6.37%
Feb-11-26 08:12AM	INmune Bio submits pre-submission package for CORDStrom with MHRA (TipRanks)
Feb-10-26 08:00AM	INmune Bio Advances CORDStrom Towards UK Marketing Authorization in RDEB (GlobeNewswire)
Jan-27-26 09:25AM	INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives (GlobeNewswire) +7.78%
Dec-05-25 07:00AM	Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom Platform (GlobeNewswire)
Dec-01-25 08:00AM	INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients (GlobeNewswire) -10.06%
Nov-18-25 08:00AM	INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference (GlobeNewswire)
09:55AM	Loading…
Nov-06-25 09:55AM	INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) -7.91%
Oct-30-25 11:03PM	INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ... (GuruFocus.com) +5.78%
04:05PM	INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update (GlobeNewswire)
Oct-23-25 07:00AM	INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 (GlobeNewswire)
Oct-14-25 07:00AM	INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 (GlobeNewswire)
Sep-29-25 08:00AM	INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal (GlobeNewswire)
Sep-15-25 08:00AM	INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom at CGT Catapult (GlobeNewswire)
Sep-08-25 04:50PM	INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -7.18%
Aug-07-25 04:05PM	INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes (GlobeNewswire) -8.24%
Aug-04-25 08:00AM	INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment (GlobeNewswire) +11.52%
Jul-31-25 07:00AM	INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th (GlobeNewswire)
Jul-29-25 07:00AM	INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro Presented at the Alzheimer's Association International Conference (GlobeNewswire) +8.59%
Jul-24-25 07:00AM	INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimer's Association International Conference (GlobeNewswire)
Jul-01-25 01:37PM	INmune slides again as Scotiabank, RJ cut ratings after Alzheimers drug miss (Investing.com) -9.52%
Jun-30-25 04:05PM	INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -56.66%
08:16AM	Loading…
08:16AM	INmune Bio stock plummets after mixed Phase 2 Alzheimers trial results (Investing.com)
07:30AM	INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro in Early Alzheimer's Disease (GlobeNewswire)
Jun-27-25 12:16PM	INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -15.13%
Jun-26-25 04:00PM	INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th (GlobeNewswire) -14.79%
Jun-10-25 04:00PM	XPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense (GlobeNewswire)
May-14-25 08:00AM	INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) -7.82%
May-08-25 04:10PM	INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update (GlobeNewswire)
May-07-25 11:23AM	INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-05-25 07:00AM	INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th (GlobeNewswire)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-16-25 07:00AM	INmune Bio Receives Favorable Patentability Opinion for CORDStrom Platform Technology (GlobeNewswire)
Apr-15-25 07:42AM	INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms (Pharmaceutical Business Review)
Apr-14-25 08:00AM	INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom Manufacturing for Commercial Readiness (GlobeNewswire)
Apr-01-25 07:00AM	INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study (GlobeNewswire)
Mar-28-25 03:04AM	INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Mar-27-25 08:15PM	INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update (GlobeNewswire)
Mar-24-25 08:00AM	INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-21-25 01:15PM	Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + (SeekingAlpha)
Mar-02-25 09:28AM	Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-12-25 09:51AM	INmune Bio price target raised to $23 from $22 at Scotiabank (TipRanks) +10.67%
07:00AM	INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer (GlobeNewswire)
Feb-10-25 07:00AM	INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Feb-03-25 08:11PM	Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 (Insider Monkey)
Jan-28-25 08:00AM	INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans (GlobeNewswire)
Jan-12-25 06:05AM	Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks (TipRanks)
Dec-10-24 08:00AM	INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt (GlobeNewswire)
Dec-04-24 02:51PM	OmniScience and INmune Bio Partner for Alzheimers Trial (Exec Edge)
09:00AM	OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower (Business Wire)
Nov-13-24 09:00AM	INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Nov-01-24 11:01AM	INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... (GuruFocus.com)
Oct-31-24 04:05PM	INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Oct-30-24 09:22AM	INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.56%
Oct-28-24 08:00AM	INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB (GlobeNewswire) +13.75%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares (GuruFocus.com)
Oct-24-24 03:03PM	INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro Promotes Remyelination (GlobeNewswire)
09:30AM	INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 (GlobeNewswire)
Oct-11-24 08:30AM	INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-09-24 03:51PM	INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 08:00AM	INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Sep-26-24 08:00AM	INKmune Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort (GlobeNewswire)
Sep-17-24 08:30AM	INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints (GlobeNewswire)
Sep-13-24 08:30AM	INmune Bio Announces $13.0 Million Registered Direct Offering (GlobeNewswire) -14.55%
Sep-03-24 09:00AM	INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference (GlobeNewswire) -7.10%
Aug-01-24 04:05PM	INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update (GlobeNewswire) -7.92%
Jul-29-24 09:00AM	INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro on Proteins that Regulation Synapses in Alzheimer's Patients (GlobeNewswire)
Jul-25-24 08:00AM	INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 (GlobeNewswire)
Jul-23-24 08:45AM	INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Jun-28-24 12:13PM	INmune Bios unique Alzheimers trial endpoint receives validation (Clinical Trials Arena)
Jun-27-24 08:00AM	INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial (GlobeNewswire) +19.20%
May-30-24 08:00AM	INmune Bio Inc. to Join Russell 3000 Index (GlobeNewswire)
May-13-24 11:54AM	INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:05PM	INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update (GlobeNewswire) -6.96%
May-07-24 08:00AM	INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 (GlobeNewswire)
Apr-30-24 08:00AM	INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years (GlobeNewswire)
Apr-29-24 08:00AM	INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Apr-25-24 09:00AM	INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Apr-23-24 08:00AM	INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay (GlobeNewswire)
Apr-22-24 08:00AM	INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering (GlobeNewswire) +26.94%
Apr-08-24 08:00AM	INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 (GlobeNewswire)
Apr-01-24 10:20AM	INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31PM	INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements (GuruFocus.com)
Mar-28-24 08:53PM	INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update (GlobeNewswire)
Mar-26-24 04:01PM	INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 (GlobeNewswire)
Mar-13-24 08:00AM	INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy (GlobeNewswire)
Mar-05-24 08:00AM	INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro (GlobeNewswire) -5.37%
Feb-12-24 09:00AM	INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-24 09:00AM	INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024 (GlobeNewswire)
Jan-30-24 08:00AM	INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program (GlobeNewswire) -7.52%

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer's disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INMB

INmune Bio Inc

Upgrade your Finviz experience